Plant ID: NPO28669
Plant Latin Name: Cuscuta australis
Taxonomy Genus: Cuscuta
Taxonomy Family: Convolvulaceae
NCBI TaxonomyDB:
267555
Plant-of-the-World-Online:
267308-1
Turkey; Madagascar; Italy; Bangladesh; Sudan; Hungary; France; Ethiopia; Somalia; Nigeria; Cameroon; Cote d'Ivoire; Turkmenistan; Ghana; Australia; Iran; Algeria; Zambia; China; Kazakhstan; Sierra Leone; Ukraine; Liberia; Tanzania; Indonesia; Morocco; Vietnam; Japan; Switzerland; Russia; Bulgaria; Portugal; South Africa; Tunisia; India; Uzbekistan; Uganda; Greece; Kenya; Taiwan; Tajikistan; Botswana
TSHR; NPSR1; | |
FFAR1; FFAR4; | |
ACHE; | |
MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; CSNK2A1; | |
CA2; CA12; CA7; CA4; | |
PPARA; | |
ESR2; | |
TYR; XDH; | |
ALOX12; HSD17B1; CBR1; HSD17B2; HSD17B10; NOX4; ALOX15; POLB; | |
AHR; | |
LMNA; FABP3; FABP5; THPO; APP; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.782E-10 | 1.012E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.408E-09 | 2.253E-06 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.634E-09 | 4.396E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.344E-08 | 1.963E-05 | CA12, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.018E-07 | 5.835E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.502E-07 | 8.246E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.798E-07 | 1.296E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.795E-07 | 3.677E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.960E-06 | 6.776E-04 | AXL, CA2, CSNK2A1, CYP1A1, CYP1A2, FABP3, FFAR1, FLT3, HSD17B2, TYR |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.086E-06 | 7.096E-04 | APP, CA2, CDK1, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4, TYR |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.230E-06 | 7.470E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.501E-06 | 7.894E-04 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 3.383E-06 | 1.009E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.483E-06 | 1.025E-03 | ALOX15, APP, FFAR4, KDR, NOX4, THPO |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.396E-06 | 1.196E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.396E-06 | 1.196E-03 | ALOX12, ALOX15 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 8.977E-06 | 2.211E-03 | ALOX12, AURKB, AXL, CDK1, CSNK2A1, FFAR4, IGF1R, KDR, LMNA, PIM1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.317E-05 | 2.898E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.317E-05 | 2.898E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.317E-05 | 2.898E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.526E-05 | 3.323E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 1.781E-05 | 3.730E-03 | ACHE, ALOX12, ALOX15, CSNK2A1, CYP19A1, CYP1A1, HSD17B1, HSD17B2 |
MF | GO:0060089; molecular transducer activity | GO:0038023; signaling receptor activity | 1.859E-05 | 3.855E-03 | AHR, AXL, ESR2, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, PPARA, TSHR |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.007E-05 | 4.008E-03 | AXL, CDK1, CSNK2A1, FLT3 |
BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 2.139E-05 | 4.234E-03 | ALOX12, APP, CA12, CA2, CA7, FABP3, FFAR1, MET, NOX4, NPSR1 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 2.506E-05 | 4.787E-03 | FABP3, FABP5, FFAR4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.630E-05 | 4.938E-03 | CYP1A1, CYP1A2 |
BP | GO:0009987; cellular process | GO:0071310; cellular response to organic substance | 3.316E-05 | 5.967E-03 | ALOX15, APP, AXL, CYP1A1, CYP1B1, FFAR4, FLT3, IGF1R, KDR, NOX4, TSHR |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 3.696E-05 | 6.542E-03 | ACHE, ALOX15, CDK1, CYP1A1, PPARA |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.218E-05 | 7.120E-03 | AHR, CSNK2A1, KDR |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 4.378E-05 | 7.222E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 4.438E-05 | 7.266E-03 | AXL, FLT3, IGF1R, KDR, MET |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.074E-05 | 8.006E-03 | CYP19A1, CYP1A1, CYP2C19 |
MF | Unclassified; | GO:0004872; receptor activity | 6.189E-05 | 9.490E-03 | AHR, AXL, ESR2, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, PPARA, TSHR |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 6.269E-05 | 9.545E-03 | CA2, CSNK2A1, CYP1A2, FABP3, FFAR4, FLT3, PPARA, TSHR |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.558E-05 | 9.781E-03 | CYP1A2, CYP2C19 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 7.530E-10 | 7.003E-08 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.895E-09 | 8.812E-08 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.458E-06 | 8.292E-05 | CBR1, HSD17B1, HSD17B2, CYP1A2, ALOX15, CYP1A1, ALOX12, CYP2C19, TYR, CYP19A1, HSD17B10, XDH |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.834E-07 | 1.589E-05 | CBR1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.547E-08 | 1.100E-06 | CA12, CA2, CA4, CA7 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 7.779E-06 | 1.206E-04 | CBR1, ALOX15, ALOX12, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.493E-05 | 1.984E-04 | CBR1, CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 8.044E-05 | 6.800E-04 | APP, ALOX15, ALOX12, CYP2C19 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 7.495E-05 | 6.800E-04 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.816E-05 | 3.273E-04 | CYP1A2, ALOX15, CYP2C19 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 4.685E-04 | 3.352E-03 | CSNK2A1, MET, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 3.814E-04 | 2.956E-03 | FABP3, FABP5, PPARA |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.009E-03 | 6.705E-03 | CA2, CA4 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.084E-05 | 4.220E-04 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; APP; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
NA: NA | Geographic retinal atrophy | NA | APP; |
C00-D49: Neoplasms | Glioma | C71 | KDR; APP; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; APP; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; APP; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
NA: NA | Edema | NA | CA2; |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP; |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
NA: NA | HIV infections | NA | AHR; |